Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

picibanil

A lyophilized formulation containing cultures of a low-virulent strain of Streptococcus pyogenes, treated and killed with pencillin G, with potential sclerosing, immunostimulating and antineoplastic activities. Besides its activity as a sclerosing agent, picibanil appears to have multiple effects on the immune system as a non-specific immunostimulant. This agent activates the host immune system by stimulating the activity of natural killer (NK) cells, macrophages and lymphocytes, and by enhancing the production of several key immune mediators, including interleukins (ILs) and tumor necrosis factor (TNF).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	OK-432

picibanil

Search NCI's Drug Dictionary